Testosterone Therapy Boca Raton: What the Label Requires Before and After

Most testosterone therapy Boca Raton men encounter is sold on a symptom list and a single blood draw. The approved labeling asks for considerably more than that, before treatment and during it, and the FDA changed the labeling for every product in this class in 2025. Both of those things are worth knowing before you walk into anywhere.

Testosterone therapy Boca Raton: what it is approved to treat

The approved wording is narrow and worth reading in full, because a great deal of what is marketed as testosterone therapy sits outside it.

The label indicates testosterone “for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone”, and names two: primary hypogonadism, congenital or acquired, and hypogonadotropic hypogonadism. Both are medical conditions with a cause.

Directly beneath that sits a Limitation of Use: “Safety and efficacy… in men with ‘age-related hypogonadism’… have not been established.” The quotation marks around age-related hypogonadism are the FDA’s own. Getting older and feeling flat is not, on the label, an indication.

That distinction is the whole of the difference between a clinic and a low testosterone storefront. It does not mean you cannot be treated — plenty of men have genuine, demonstrable deficiency and do very well. It means the finding has to be established before treatment rather than assumed from how you feel, and the next section is how the label says to establish it.

What has to be established before a first prescription

The label is specific, and it asks for more than one blood test.

“Prior to initiating… confirm the diagnosis of hypogonadism by ensuring that serum testosterone has been measured in the morning on at least two separate days and that these concentrations are below the normal range.”

Three requirements are packed into that sentence. The measurement must be in the morning, because testosterone follows a daily rhythm and an afternoon draw can read low in a man whose levels are normal. It must be on at least two separate days, because a single low result is not reliable. And the concentrations must actually be below the normal range, not merely lower than you would like.

The label also instructs that patients be evaluated for prostate cancer before starting, and that haematocrit be checked before treatment begins. Anyone who offers you a prescription after one afternoon blood draw and a questionnaire is not following the document the medicine was approved on.

What the FDA changed across the whole class in 2025

For about a decade, every testosterone product carried a boxed warning about possible increased risk of heart attack and stroke. If you researched this subject before 2025, that warning is probably what you remember.

It is no longer there. Following the TRAVERSE trial, which concluded there was no increase in the risk of adverse cardiovascular outcomes in men using testosterone, the FDA removed that boxed warning from every product in the class. That is a substantial change and it is good news for men who have been putting off a conversation because of what they read.

The same action added something. Postmarket studies confirmed an increase in blood pressure across the class, so the labeling now warns that testosterone “can increase blood pressure”, that “blood pressure increases can increase cardiovascular risk over time”, and that it is not recommended for use in patients with uncontrolled hypertension.

And the age-related limitation stayed exactly where it was. The FDA retained it in the same action that removed the cardiovascular warning, which tells you the agency reconsidered the evidence carefully rather than loosening the rules generally.

The monitoring the label asks for, with its intervals

This is the part most often skipped, and it is written into the labeling with actual timings.

The haematocrit instruction matters more than it looks. The label notes that “increases in haematocrit, reflective of increases in red blood cell mass, may require lowering or discontinuation of testosterone”. That is a decision somebody has to be positioned to make, which requires having taken the measurement on schedule.

If you are currently on testosterone and cannot remember the last time your haematocrit was checked, that is the question worth asking wherever you are being treated.

How testosterone therapy runs at Brazelia MedSpa

The programme follows the label rather than a script. Two morning measurements on separate days before anything is prescribed, the pre-treatment evaluation the labeling asks for, and the monitoring schedule above kept as a schedule rather than as an intention.

Sometimes that conversation ends with a decision that low testosterone is not the problem, and it is better to hear that than to be handed a prescription you did not need. Low energy, poor sleep, weight gain and low mood have several possible causes, and testosterone is one of them rather than all of them — which is why thyroid and metabolic markers are looked at in the same visit rather than referred out. Those are covered on the metabolic labs page.

Because Brazelia MedSpa is physician-directed on site, with Dr. Herbert R. Slavin, MD as medical director rather than a name on a licence, a result that needs a clinical decision gets one. That is the practical difference between a programme and a subscription.

New patients start with a consultation, where what would need to be established, and what the monitoring would involve, is discussed before anything is prescribed.

Frequently asked questions

Sources and how this page was built

The indication, limitation of use, diagnostic requirement and every monitoring interval on this page are read from FDA-approved testosterone labeling, revision 07/2025, and the class-wide changes from the FDA’s own announcement of them, both on 28 September 2026. Where the labeling gives a timing, that timing is reproduced rather than paraphrased. Nothing on this page is a diagnosis.

Why patients choose Brazelia MedSpa

This page is the best answer we can give. The easy version of this page lists symptoms and invites you to book. This one prints the limitation of use, the two-morning-measurement requirement and the monitoring intervals, because those are the things that separate treatment from a subscription, and a clinic willing to publish the standard it is held to is one you can hold to it.

Hormone therapy at Brazelia MedSpa is run by Khali Reed, CRNA, APRN, in a practice under the medical direction of Dr. Herbert R. Slavin, MD, on site rather than a name on a licence.

Brazelia MedSpa has treated patients from the same address in downtown Boca Raton for 18 years, near Mizner Park, and sees patients from across South Florida, from Delray Beach and Boynton Beach to Deerfield Beach and Fort Lauderdale. The programme is run by the same people every visit, which matters more on a medication you take for a year than on a treatment you have once.

Weight is also rarely treated as just weight here. Because Brazelia MedSpa runs hormone, metabolic, skin and regenerative programmes under one roof, thyroid, sleep, training load and the skin changes that follow a large weight reduction can be looked at in the same place, by people who are already talking to each other.

New patients start with a consultation, and nothing is prescribed on a first visit unless it is clinically appropriate and you want to proceed. You will hear what the label supports, what it does not, and what the plan would look like before anything is decided.

This page describes what published labels, regulatory records and peer-reviewed research report about these treatments. It is general health information, not medical advice, and it is not a substitute for a consultation. Whether any treatment is appropriate for you is a clinical judgement that depends on your history and examination.